Author:
Singh Kuldev,Spaeth George L.,Hays Ron D.,Parke David W.,Tarver Michelle E.,Eydelman Malvina
Funder
U.S. Food and Drug Administration
U.S. Department of Health and Human Services
Center of Excellence in Regulatory Science and Innovation
National Institutes of Health
American Glaucoma Society
University of California, San Francisco
Reference8 articles.
1. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime;Saunders;Invest Ophthalmol Vis Sci,2014
2. Usage patterns of minimally invasive glaucoma surgery (MIGS) differ by glaucoma type: IRIS Registry analysis 2013-2018;Yang;Ophthalmol Glaucoma,2021
3. US Food and Drug Administration. Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices - Guidance for Industry and Food and Drug Administration Staff (fda.gov). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-studies-implantable-minimally-invasive-glaucoma-surgical-migs-devices
4. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract;Samuelson;Ophthalmology,2011
5. Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery;Ahmed;Ophthalmology,2022